EGFR and lung carcinoma: Since the luminal cargo of EVs reflects the cellular context of origin and contains bioactive molecules that are actively expressed during the process of packaging and release [16], EVs released upon EGFR activation in lung cancer may carry mutated forms of EGFR, oncogenic proteins, various types of nucleic acids, and other signaling molecules.